1 **Article** 2 Title: 3 Folate receptor alpha protein expression in ovarian serous cystadenocarcinoma tumors 4 of The Cancer Genome Atlas: exploration beyond single-agent therapy 5 Authors: 6 7 Christianne Persenaire, MD¹, Benjamin G. Bitler, PhD^{1,2}, and Bradley R. Corr, MD¹ 8 1. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, 9 University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA 10 2. Department of Obstetrics & Gynecology, Division of Reproductive Sciences, 11 University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA 12 3. Correspondence: christianne.persenaire@cuanschutz.edu 13 14 **Corresponding Author:** 15 Christianne Persenaire, MD 16 1665 Aurora Court Anschutz Cancer Pavilion, 2nd Floor 17 18 Aurora, CO 80045 19 Phone: (484) 557-2111 20 Email: christianne.persenaire@cuanschutz.edu 21 22 23

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

2

Word Counts: Abstract: 199 Manuscript: 2945 Simple Summary: Epithelial ovarian cancer can be highly lethal, with limited therapeutic options for patients without BRCA mutations or non-homologous recombination deficient disease. Folate receptor alpha (FRα)-targeting agents have shown promise in the setting of platinum-sensitive and platinum-resistant ovarian cancer, both alone and in combination with available therapies, but the relationship of $FR\alpha$ to other treatment-driving biomarkers is unknown. This study identifies potential targetable mutations in FRα-expressing tumors, including PIK3CA and FGF/R family proteins, and provides a basis for future investigations of novel combinations of FRatargeting agents with PIK3CA, mTOR, FGF/R, and VEGF inhibitors. Abstract: Epithelial ovarian cancer (EOC) can be highly lethal, with limited therapeutic options for patients with non-homologous recombination deficient (HRD) disease. Folate receptor alpha (FOLR1/FRα)-targeting agents have shown promise both alone and in combination with available therapies, but the relationship of FR α to other treatmentdriving biomarkers is unknown. The Cancer Genome Atlas (TCGA) was gueried to assess protein and mRNA expression and mutational burden in patients with differential FR α protein-expressing ovarian tumors, and the results referenced against the standard 324 mutations currently tested through FoundationOne Companion Diagnostics to

identify targets of interest. Of 585 samples within TCGA, 121 patients with serous ovarian tumors for whom FR α protein expression was quantified were identified. FR α protein expression significantly correlated with FOLR1 mRNA expression (p=7.19x10⁻¹ ¹⁴). Progression free survival (PFS) for the FR α -high group (Q1) was 20.7 months, compared to 16.6 months for the FR α -low group (Q4, Logrank, p=0.886). Overall survival (OS) was 54.1 months versus 36.3 months, respectively; however, this result was not significant (Q1 vs. Q4, Logrank, p=0.200). Mutations more commonly encountered in patients with high FRα-expressing tumors included PIK3CA and FGF family proteins. Combinations of FRα-targeting agents with PI3K, mTOR, FGF(R) and VEGF inhibitors warrant investigation to evaluate their therapeutic potential. **Keywords**: epithelial ovarian cancer, folate receptor alpha, mirvetuximab soravtansine. serous ovarian adenocarcinoma, targeted therapeutics

1. Introduction:

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

Ovarian cancer is the second most common gynecologic malignancy affecting women in the United States and accounts for more deaths than all other gynecologic malignancies combined. The standard of care for women with epithelial ovarian cancer (EOC), including ovarian, fallopian tube, and primary peritoneal cancers, remains a combination of cytoreductive surgery and taxane/platinum-based chemotherapies. However, despite advancements in treatment with approved targeted therapies such as poly(ADP-ribose) polymerase (PARP) inhibitors and vascular endothelial growth factor (VEGF) inhibitors, disease recurrence still occurs at an alarming rate of 70-80% [1]. Recurrent disease most commonly progresses to a non-curable, platinum-resistant state, and there remains a critical need to develop new therapeutic approaches. Over the past decade, folate and its membrane-bound receptor have garnered increased interest as a potential molecular target, as rapidly dividing cancer cells are highly dependent on folate metabolism for DNA replication [2]. Folate receptor alpha (FOLR1/FRα), specifically, is a transmembrane protein involved in cellular folate transport whose expression is highly restricted in somatic tissues. Approximately 80% of EOC constitutively overexpress this receptor, and elevated expression has been found to be associated with a more aggressive tumor phenotype [3]. FRα-targeting agents range in design from monoclonal antibodies and small molecules to folate-drug and antibody-drug conjugates (ADCs). Farletuzumab, for example, is a fully humanized IgG1 antibody that targets FR α -positive cancer cells, while CT900 is a

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

small molecule thymidylate synthase inhibitor that is transported into tumor cells by its high affinity for the FR α receptor [4]. Vintafolide is a folate-drug conjugate in which a water-soluble folic acid derivative is linked through a peptide spacer to a potent microtubule destabilizing agent called desacetylvinblastine monohydrazide, a vinca alkaloid [4]. Once released within the cell, the vinca alkaloid acts to inhibit the betatubulin polymerization necessary for cell division to induce cell cycle arrest. ADCs are a novel class of antineoplastic agents that can utilize FR α as a biomarkerdriven target. These entities typically consist of a monoclonal antibody directed against a tumor-associated antigen to which a cytotoxic agent ('payload') is conjugated; once internalized, the payload is released to mediate its cytotoxic effects. This design has the theoretical benefit of minimizing systemic toxicity while maximizing efficacy [5], and the inherent capacity of FR α to internalize large molecules makes the receptor ideally suited for targeting with ADCs such as mirvetuximab soraytansine (MIRV), STRO-002, and MORab-202. Along with farletuzumab, these ADCs, as well as ELU001, a C'Dot

MIRV is an ADC with the most clinical evaluation in EOC of its drug class to date. It is comprised of an FR α -binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent. Upon antigen binding, the FR α -ADC complex is rapidly

drug conjugate (NCT05001282); TPIV200/hu-FR-1, a multi-epitope anti-folate receptor

vaccine (NCT02764333) [6]; and ITL-306, a cell-based therapy derived from tumor-

infiltrating lymphocytes (TIL) whose activity increases when the agent encounters

tumor-specific FR α (NCT05397093); are under active investigation.

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

internalized and DM4 is released to induce cell cycle arrest and apoptosis. MIRV has the additional benefit of bystander killing, as the cleavable linker design allows active DM4 metabolites to diffuse from the antigen-positive tumor cells into neighboring cells [7]. STRO-002 is another FR α -specific ADC comprised of an anti-FR α human IgG1 antibody, SP8166, conjugated to a cleavable DBCO-3-aminophenyl-hemiasterlin druglinker, while MORab-202 is an ADC in which farletuzumab and eribulin, a microtubule inhibitor, are linked via cleavable cathepsin B [8]. Early clinical studies of MIRV in patients with platinum-resistant ovarian cancer (PROC) showed promise, with an objective response rate (ORR) of 39% in a phase Ib trial with few grade 3/4 toxicities [9]. In November of 2022, MIRV was granted accelerated approval for FR α positive platinum-resistant ovarian cancer based on results from the SORAYA trial (NCT04296890). Single-agent use in patients with up to three prior lines of therapy, including required bevacizumab, demonstrated an ORR of 32.4%, including five complete responses (CR), and a median duration of response (DOR) of seven months. Response rates were similar regardless of the number of prior therapies received, including PARP inhibitors [10]. More recently, encouraging results from the international phase III randomized controlled trial, MIRASOL, comparing MIRV to investigator's choice chemotherapy (IC) in patients with FR α positive PROC, were presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO). Study authors found the median overall survival (OS) was 16.5 months with MIRV vs. 12.8 months with IC (HR 0.67, p = 0.0046), while the median progression free

survival (PFS) was 5.62 months vs 3.98 months in each respective arm (HR 0.65, p.

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

7

the objective of this study was to analyze TCGA to assess protein/mRNA expression

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183




Figure 1: (A) Consort diagram establishing the TCGA PanCancer Atlas patient population for whom FRα expression data were available. (B) Columnar scatter plot of FRα protein expression values by quartile. (C) Columnar scatter plot of FRα mRNA expression by quartile. (D) Scatter plot depicting Pearson correlation of 0.75 between FOLR1 mRNA transcription and FRα protein expression. (E) Kaplan Meier curves depicting overall survival (OS) and progression free survival (PFS) by quartile.

3. Results:

Utilizing TCGA PanCancer Atlas (n=585), we identified 121 patients with serous ovarian tumors for whom FR α protein expression was quantified. Those patients were then

stratified into quartiles to assess for correlation with outcomes of interest (Figure 1A-B). TCGA PanCancer Atlas comparison of mRNA expression, protein expression (CPTAC) and genomic alterations was utilized across the four quartiles and data collected for 18,695 mRNA transcripts and 7,620 proteins. Both mRNA expression and protein expression of FR α decreased in stepwise fashion from Q1 to Q4 (Figure 1B-C), and FOLR1 mRNA expression was significantly elevated (t-test; p=7.19x10⁻¹⁴; FDR q=6.78x10⁻¹⁰) across the different quartiles (Figure 1C). The Pearson correlation between FOLR1 mRNA transcription and FR α protein expression was 0.7452 (p<0.0001, Figure 1D).

When evaluating survival outcomes by quartile, PFS for the FR α -high group (Q1) was 20.7 months, compared to 16.6 months for the FR α -low group (Q1 vs Q4, Logrank, p=0.886). Overall survival was 54.1 months versus 36.3 months, respectively; however, this result was not significant (Q1 vs. Q4, Logrank, p=0.200) (Figure 1E, Table 1).

Table 1: Overall survival and progression free survival in patients with EOC stratified by levels of tumor FRα expression; p-values derived by Log Rank test.

	Q1 (High FOLR1)	Q2 (High Int. FOLR1)	Q3 (Low Int FOLR1)	Q4 (Low FOLR1)	p-value	
Overall Survival	54.1	31.3	39.4	36.3	0.3	
Months (95% CI)	(43.2-NA)	(20.9-74.9)	(33.9-NA)	(24.2-70.1)	0.3	
Progression Free Survival	20.7	14.5	16	16.6	0.4	
Months (95% CI)	(12.9-27.8)	(11.8-19.6)	(13.0-26.9)	(11.54-NA)	0.4	

215

216

217

218

219

220

221

222

223

224

225

226

	Number of mutations (%)							
Gene Symbol	Q1 (High FOLR1)	Q2 (High Int. FOLR1)	Q3 (Low Int FOLR1)	Q4 (Low FOLR1)	p-value			
PIK3CA	9 (29.03%)	5 (16.67%)	7 (23.33%)	6 (20.69%)	0.703			
ETV5	7 (22.58%)	6 (20.00%)	4 (13.33%)	4 (13.79%)	0.724			
FGF12	7 (22.58%)	7 (23.33%)	6 (20.00%)	4 (13.79%)	0.793			
KLHL6	7 (22.58%)	6 (20.00%)	4 (13.33%)	6 (20.69%)	0.814			
RAD21	7 (22.58%)	9 (30.00%)	11 (36.67%)	7 (24.14%)	0.61			
CCND1	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507			
FGF19	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507			
FGF3	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507			
FGF4	6 (19.35%)	2 (6.67%)	2 (6.67%)	0 (0.00%)	0.0507			
MAP3K13	6 (19.35%)	7 (23.33%)	5 (16.67%)	4 (13.79%)	0.807			
SOX2	6 (19.35%)	5 (16.67%)	5 (16.67%)	6 (20.69%)	0.971			
IRF4	5 (16.13%)	3 (10.00%)	4 (13.33%)	1 (3.45%)	0.431			
TIPARP	5 (16.13%)	3 (10.00%)	4 (13.33%)	3 (10.34%)	0.876			
ERBB4	5 (16.13%)	2 (6.67%)	1 (3.33%)	0 (0.00%)	0.0698			
ATR	5 (16.13%)	4 (13.33%)	2 (6.67%)	1 (3.45%)	0.332			
TERT	4 (12.90%)	3 (10.00%)	2 (6.67%)	0 (0.00%)	0.266			
BCL6	4 (12.90%)	6 (20.00%)	4 (13.33%)	5 (17.24%)	0.856			
RSPO2	4 (12.90%)	8 (26.67%)	3 (10.00%)	7 (24.14%)	0.257			
XRCC2	4 (12.90%)	4 (13.33%)	4 (13.33%)	1 (3.45%)	0.539			
BRD4	4 (12.90%)	2 (6.67%)	0 (0.00%)	6 (20.69%)	0.0532			
NOTCH3	4 (12.90%)	2 (6.67%)	1 (3.33%)	6 (20.69%)	0.149			
SDHA	4 (12.90%)	3 (10.00%)	2 (6.67%)	0 (0.00%)	0.266			
CCNE1	4 (12.90%)	4 (13.33%)	5 (16.67%)	7 (24.14%)	0.632			
BRAF	4 (12.90%)	5 (16.67%)	3 (10.00%)	4 (13.79%)	0.899			
ERBB3	4 (12.90%)	1 (3.33%)	0 (0.00%)	1 (3.45%)	0.113			
MCL1	4 (12.90%)	2 (6.67%)	1 (3.33%)	2 (6.90%)	0.552			
BRCA1	3 (9.68%)	1 (3.33%)	1 (3.33%)	.33%) 2 (6.90%)				
BTG2	3 (9.68%)	2 (6.67%)	0 (0.00%)	1 (3.45%)	0.344			
CDKN1A	3 (9.68%)	3 (10.00%)	1 (3.33%)	0 (0.00%)	0.27			
FOXL2	3 (9.68%)	4 (13.33%)	1 (3.33%)	1 (3.45%)	0.373			

Table 3: Proteins with an absolute Spearman's Rho >0.98 suggesting association with FOLR1 expression; p-values derived by student's t-test.

		FOLR1 Protein Expression (Z-score)					
Gene Symbol	Gene Name	Q1 (High)	Q2 (High In	Q3 (Low Int	Q4 (Low)	Rho value	p-value
CTNNA1	alpha catenin	0.14	0.03	-0.02	-0.07	0.991	0.002
FH	fumarate hydratase	0.16	0	-0.05	-0.12	0.985	0.013
CDH1	e-cadherin	0.09	0.01	-0.08	-0.21	0.984	0.008
SDHA	succinate dehydrogenase complex flavoprotein subunit A	0.09	0	-0.01	-0.07	0.981	0.110
SRC	proto-oncogene C-Src	-0.08	-0.05	0.01	0.05	-0.977	0.271
AKT3	protein kinase B, gamma	-0.2	-0.01	0.04	0.12	-0.981	0.529
NF1	neurofibromin 1	-0.09	-0.06	-0.01	0.03	-0.982	0.627
QKI	quaking homolog, KH domain RNA binding	-0.05	0.03	0.07	0.13	-0.999	0.012

Only 160/324 genes on the FoundationOne CDx were identified via CPTAC. Quaking Homolog, KH Domain RNA Binding (QKI) was the most negatively correlated (Pearson r = -0.996) and Alpha Thalassemia/Mental Retardation Syndrome X-Linked (ATRX) was the most positively correlated (Pearson r = 0.993). BRCA1 protein expression was undetectable and BRCA2 protein expression did not correlate with FR α protein expression (Pearson r = 0.27). Data regarding protein expression for other genes in the HRD pathway were available only for ATM, CHEK2 and NBS1, and also showed no correlation.

4. Discussion:

Targeting FR α is an area of active investigation and one that holds significant promise. In this study, we used TCGA to identify potential molecular targets that could potentiate

the ORR of FR α -targeting agents and improve their therapeutic efficacy for patients with EOC, particularly those with non-HRD, platinum-resistant disease. We identified an increased frequency of potentially targetable PIK3CA and FGF family protein mutations in FR α -expressing tumors.

Results in the Context of Published Literature:

Although early studies of single-agent MIRV, STRO-002, and MORAb-202 suggested these have anti-tumor activity, several combinatorial approaches are under active investigation. MIRV, for example, is being studied in combination with various chemotherapies and targeted therapies such as pembrolizumab and bevacizumab (NCT02606305). In 2018, as part of FORWARD II, Moore et al. published data from the phase 1b escalation study of MIRV in combination with carboplatin in patients with platinum-sensitive ovarian cancer (PSOC), which found a 71% ORR, including three CR and nine PR, and a median PFS of 15 months [19]. Among others, these findings prompted a single arm, phase II trial of carboplatin and MIRV for first-line treatment of patients with advanced, FR α -positive EOC receiving neoadjuvant chemotherapy (NCT04606914). A randomized phase II trial of MIRV in FR α -high, recurrent PSOC also began enrolling patients in September 2021, with the goal of comparing platinum-based chemotherapy followed by PARPi (if indicated) to carboplatin + MIRV followed by MIRV monotherapy (NCT04274426).

For patients with PROC, another expansion cohort from FORWARD II found a confirmed ORR of 43% in patients treated with a combination of MIRV and

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

pembrolizumab, with a median DOR of 6.9 months and median PFS of 5.2 months [20]. The same phase Ib study included a cohort of patients with PROC who received MIRV in combination with bevacizumab; for these patients, the confirmed ORR was 39%. including five CR and 21 PR; median PFS was 6.9 months. Patients who were bevacizumab-naïve, less heavily pretreated, and whose tumors had medium/high FRa expression had an ORR of 56% with a median DOR of 12 months and PFS of 9.9 months [21]. Given these findings, FORWARD II looked at the combination of MIRV, carboplatin and bevacizumab followed by MIRV and bevacizumab maintenance therapy in 41 patients with recurrent PSOC, with a confirmed ORR of 83%, median DOR of 10.9 months and PFS of 12.8 months [22]. These data suggest synergistic and durable antitumor effects of combinatorial approaches, and more trials are in active development. In our effort to identify potential targets, we found PIK3CA is mutated in 29% of tumors with high FR α expression. PIK3CA, or phosphatidylinositol-4,-5-bisphosphanate 3kinase catalytic subunit alpha, is an oncogene that has been implicated in several cancers, including breast, colon, liver, and stomach cancers [23]. Point mutations in this gene can cause hyperactivation of the alpha isoform (p110a) of PI3K, which in turn results in constitutive activation of the intracellular PI3K/Akt signaling pathway. This pathway is linked to several critical physiologic and pathophysiologic functions, including those that drive tumor progression, such as cell proliferation, growth, metabolism, angiogenesis, and motility [24]. Several PI3K inhibitors, such as alpelisib, a small molecule, a-specific PI3K inhibitor that selectively inhibits p110a, are being evaluated, and early work suggests that PIK3CA-mutated cancers are sensitive to

treatment with these agents [25]. When given in combination with standard of care therapies, as with olaparib in ovarian cancer or fulvestrant in breast, these drugs may work synergistically to overcome tumor resistance and sensitize the tumor cells to treatment with currently approved agents [26, 27].

The propensity toward PIK3CA mutations in FR α high tumors also provides a basis for investigating combinations of FR α -targeting agents with mammalian target of rapamycin, or mTOR, inhibitors. This is because activation of the PI3K/Akt signaling pathway results in downstream activation of the mTOR pathway. As with the PI3K/Akt pathway, mTOR plays a key role in regulating cell proliferation, and functions as a regulator of autophagy and apoptosis; thus, alterations in this pathway can lead to unchecked cell proliferation. In ovarian cancer, specifically, the PI3K/Akt/mTOR pathway has been found to activated in approximately 70% of cases and has been linked to higher invasive and migratory capacity. The mTOR inhibitors temsirolimus and everolimus have been studied in clinical trials of patients with recurrent EOC and had promising results [28].

Importantly, while VEGF was not one of the top mutations identified based on FR α expression, receptor binding of VEGFR2 has been found to activate PI3K and Akt. Although the mechanism by which this occurs is not fully understood, it is thought to occur by TSAd-mediated activation of Src family kinases, which engage the receptor tyrosine kinase Axl to trigger ligand-independent autophosphorylation and promote association with PI3K and activation of Akt [29]. This association between VEGFR2 and

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

PI3K/Akt activation, as well as the higher rate of PIK3CA mutations in FR α -high tumors, may provide a mechanistic basis for the promising therapeutic efficacy seen in the early trials of patients treated with combinations of MIRV with bevacizumab mentioned previously. A phase 3 trial to evaluate MIRV in combination with bevacizumab versus bevacizumab alone in PSOC (GLORIOSA) began recruiting patients in December 2022 (NCT 05445778). Other mutations more frequently observed in FR α -high tumors were those of the fibroblast growth factor, or FGF, family, including FGF3 (19.35% vs. 0%), FGF4 (19.35% vs. 0%), FGF12 (22.58% vs. 13.79%), and FGF19 (19.35% vs. 0%). Broadly speaking, the fibroblast growth factor receptor (FGFR) family of receptor tyrosine kinases consists of four transmembrane receptors, FGFR1-4, and twenty-two known FGF ligands that interact to activate downstream signaling pathways through an intracellular domain. One such pathway is the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway, which promotes cell survival, proliferation, angiogenesis, and differentiation—processes exploited in malignant transformation and tumorigenesis [30]. Several agents targeting FGF have been developed for clinical use, ranging from selective tyrosine kinase inhibitors and monoclonal antibodies to ADCs and FGF ligand traps. Two anti-FGFR therapies have been approved by the Food and Drug Administration to date, including erdafitinib for FGFR-3-altered urothelial cancer, and pemigatinib for FGFR-2 fusion cholangiocarcinoma [30]. Lenvatinib, an oral receptor tyrosine kinase inhibitor that has activity against FGFR1-4, as well as VEGFR1-3, platelet derived growth factor receptorbeta, and the RET and kit proto-oncogenes, is currently approved for patients with advanced endometrial cancer without microsatellite instability. Given the higher FGF mutation rate seen in FR α -high tumors in this study, investigation into combinations of FR α -targeting therapies with anti-FGF/R modalities may prove a fruitful area of inquiry. It should be noted that the BRCA and HRD pathway genes did not demonstrate a clear correlation with FR α expression. The combinatory strategy with PARP inhibitors was first assessed in NCT03552471 utilizing MIRV and rucaparib in recurrent ovarian, fallopian tube, peritoneal or endometrial cancers. The ORR was 29% in the ovarian cancer cohort with a PFS >6months in 47.1% [31]. The lack of correlation of FR α expression and BRCA/HRD demonstrates that a synergistic effect between the two is unlikely, but an additive effect in distinct patient populations may warrant future investigation.

Strengths and Limitations:

A pitfall from previous trials was the method of determining FR α expression in primary tumors, which is critical, as subsequent trials observed a strong positive correlation between FR α expression and ORR. One of the strengths of this analysis was the finding that FR α protein expression significantly correlates with FOLR1 mRNA expression. This raises the possibility of examining mRNA expression in lieu of immunohistochemical based assays in future studies. Limitations of this study include those intrinsic to the use of publicly available datasets such as TCGA PanCancer Atlas, which has restricted scope with a limited number of analyzed samples. In this case, data regarding FR α

Author Contributions:

to submit the article for publication.

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

References:

- 1. Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian
- 408 cancer. Ann Oncol. 2017;28(suppl 8):viii51-viii56. Doi:10.1093/annonc/mdx441
- 409 2. Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD. Folate and folate
- receptor alpha antagonists mechanism of action in ovarian cancer. *Gynecol Oncol*.
- 411 2013;131(2):493-498.
- 3. Cheung A, Bax HJ, Josephs DH, et al. Targeting folate receptor alpha for cancer
- 413 treatment. *Oncotarget*. 2016;7(32):52553-52574.
- 414 4. Scaranti M, Cojocaru E, Banerjee S, Banerji U. Exploiting the folate receptor α in
- 415 oncology. *Nat Rev Clin Oncol*. 2020;17(6):349-359. doi:10.1038/s41571-020-0339-5
- 5. Lee EK, Liu JF. Antibody-drug conjugates in gynecologic malignancies. *Gynecol*
- 417 *Oncol.* 2019;153(3):694-702.
- 418 6. Zamarin D, et al; Abstract AP27: A phase 2 study of TPIV200/HUFR-1 (a multi-
- 419 epitope folate receptor alpha vaccine) in combination with durvalumab in patients
- with platinum resistant ovarian cancer. *Clin Cancer Res* 15 November 2019; 25
- 421 (22 Supplement): AP27. https://doi.org/10.1158/1557-3265.OVCASYMP18-AP27
- 422 7. Moore KN, Oza AM, Colombo N, et al. Phase III, randomized trial of mirvetuximab
- soravtansine versus chemotherapy in patients with platinum-resistant ovarian
- 424 cancer: primary analysis of FORWARD I. Ann Oncol. 2021;32(6):757-765.
- 425 8. Manzano A, Ocaña A. Antibody-Drug Conjugates: A Promising Novel Therapy for
- 426 the Treatment of Ovarian Cancer. Cancers (Basel). 2020;12(8):2223. Published
- 427 2020 Aug 9. Doi:10.3390/cancers12082223

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

9. O'Malley DM, Matulonis UA, Birrer MJ, et al. Phase lb study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157(2):379-385. 10. ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting. BusinessWire. 19 Mar 2022. Accessed 25 Aug 2022. Online, Available https://investor.immunogen.com/news-releases/news-release-details/immunogen- presents-full-results-positive-pivotal-soraya-trial> n.pag 11. Moore KN, Angelergues A, Konecny GE, Banerjee SN, Pignata S, Colombo N, et al. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soraytansine vs. investigator's choice of chemotherapy in platinum-resistant. advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. JCO. 2023 Jun 10;41(17 suppl):LBA5507-LBA5507. 12. Naumann RW, Marin LP, Oaknin, A, et al. STRO-002-GM2: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer. Abstract presented at ASCO 2022 Annual Meeting, Chicago, IL. 13. Shimizu T, Fujiwara Y, Yonemori K, et al. First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors. Clin Cancer Res. 2021;27(14):3905-3915. Doi:10.1158/1078-0432.CCR-20-4740 14. Konner JA, Bell-McGuinn KM, Sabbatini P, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010;16(21):5288-5295. doi:10.1158/1078-0432.CCR-10-0700 15. Lorusso PM, Edelman MJ, Bever SL, et al. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J Clin Oncol. 2012;30(32):4011-4016. doi:10.1200/JCO.2011.41.4946 16. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol 2013;31:4400-4406. 17. Ponte JF, Ab O, Lanieri L, et al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. *Neoplasia*. 2016;18(12):775-784. Doi:10.1016/j.neo.2016.11.002 18. Data used in this publication were generated by the Clinical Proteomic Tumor Analysis Consortium (NCI/NIH) 19. Moore KN, O'Malley DM, Vergote I, et al. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

Databases (2022) pp 27-56

with platinum-sensitive ovarian cancer. Gynecol Oncol, 2018:151(1):46-52. Doi:10.1016/j.ygyno.2018.07.017 20. Matulonis U, Moore KN, Martin, LP, Vergote IB, Castro C, Gilbert L, Malek K, Birrer MJ, O'Malley DM. Mirvetuximab soravtansine, a folate receptor alpha (FR α)targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase lb study. Abstracts Gynaecological Cancer 10/2018: Vol 29 Supplement 8, VIII339. doi:10.1093/annonc/mdy285.157. 21. O'Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157(2):379-385. Doi:10.1016/j.ygyno.2020.01.037 22. O'Malley DM, Richardson DL, Vergote IB, Gilbert L, Castro C, Provencher D, Matulonis UA, Mantia-Smaldone G, Martin L, Zweidler-McKay PA, Moore KN. Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibodydrug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients with recurrent platinum sensitive ovarian cancer. Annals of Oncology (202) 31 (supp 4):S551-S589. DOI: 10.1016/annonc/annonc276. 23. Safran M, Rosen N, Twik M, BarShir R, Iny Stein T, Dahary D, Fishilevich S, and Lancet D. The GeneCards Suite Chapter, Practical Guide to Life Science

495

496

497

498

499

500

501

502

503

504

505

507

508

509

510

511

512

513

514

516

24. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006;94(4):455-459. doi:10.1038/sj.bjc.6602970 25. Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. Pl3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. Int J Mol Sci. 2021;22(7):3464. Published 2021 Mar 27. doi:10.3390/ijms22073464 26. Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019;20(4):570-580. doi:10.1016/S1470-2045(18)30905-7 27. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904 506 28. Gasparri ML, Bardhi E, Ruscito I, et al. PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track? Geburtshilfe Frauenheilkd. 2017;77(10):1095-1103. doi:10.1055/s-0043-118907 29. Ruan GX, Kazlauskas A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J. 2012;31(7):1692-1703. doi:10.1038/emboj.2012.21 30. Krook MA, Reeser JW, Ernst G, et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2021;124(5):880-892. doi:10.1038/s41416-020-01157-0 31. Backes F, Fowler J, Copeland L, Wei L, O'Malley D, Cohn D, Cosgrove C, Hays J, 515 Bixel K. Phase I Study of Mirvetuximab Soravtansine (Mirv) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

- International Journal of Gynecological Cancer. 2021;31:A13-A4. doi: 10.1136/ijgc-
- 518 2021-IGCS.24. PubMed PMID: WOS:000773625600025.